retatrutide clinical trials safety Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Starting Phase 3b Clinical Trial

Take the Find My Path quiz to see what fits your body and goals, or read how Josie compares to Hers

Some studies have suggested that rapid improvements in glycemic control with semaglutide may be associated with temporary worsening of diabetic retinopathy in certain patients, particularly those with pre-existing retinopathy

Thigh tissue typically absorbs semaglutide at a marginally slower rate than abdominal tissue, though the clinical difference is usually minor across a weekly injection schedule

J Pharmacol Exp Ther 329(1):102111

They can include: As retatrutide is still being investigated, not all serious side effects are known